ZDHHC9 and neoplasm: Strikingly, this effect was abrogated when ZDHHC9 was silenced or when tumor cells were treated with Imatinib, suggesting that ZDHHC9 activity in tumor cells is required for secreting factor(s) – likely including MIF – that skew macrophages to an alternative (M2) phenotype.